It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
In Vivo's editors, along with experts from the Informa Pharma Intelligence team, have selected our top five picks for the most significant M&A, alliance and financing deals of 2021. Vote now in the polls below.
Ionis Pharmaceuticals, Inc. and AstraZeneca PLC engaged in a strategic cooperation agreement to develop and commercialize eplontersen, Ionis' experimental antisense medication for the treatment of transthyretin amyloidosis (ATTR)....
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
